Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1845799 | 1.00 | BCAT2 (0.41) | BCAT2ALDH1A1LMNAKDM4ETSHR | |
| SCHEMBL1845950 | 0.84 | AXL (0.41) | ALDH1A1LMNAKDM4ETSHRGAA | |
| SCHEMBL1845952 | 0.84 | AXL (0.41) | ALDH1A1LMNAKDM4ETSHRGAA | |
| SCHEMBL12083533 | 0.80 | GAA (0.38) | ALDH1A1LMNAKDM4EGAASMN1; SMN2 | |
| SCHEMBL1847139 | 0.80 | KMT2A (0.48) | ALDH1A1LMNAKDM4ESMN1; SMN2PKM | |
| SCHEMBL1847138 | 0.80 | KMT2A (0.48) | ALDH1A1LMNAKDM4ESMN1; SMN2PKM | |
| SCHEMBL12083501 | 0.76 | MAOB (0.37) | ALDH1A1TSHRMEN1KMT2AMAPK8 | |
| SCHEMBL1847786 | 0.76 | MAOB (0.37) | ALDH1A1TSHRMEN1KMT2AMAPK8 | |
| SCHEMBL12083528 | 0.74 | TSHR (0.37) | ALDH1A1LMNAKDM4ETSHRKMT2A | |
| SCHEMBL15936362 | 0.73 | NPC1 (0.35) | MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2324006-B1 | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD (IN) | 2014-08-13 | — | — | EP | claimed |
| US-8258119-B2 | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | Kasina Laila Innova Pharmaceuticals (IN) | 2012-09-04 | — | — | US | claimed |
| EP-2324006-A2 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | Kasina Laila Innova Pharmaceuticals Private Ltd. (IN) | 2011-05-25 | — | — | EP | claimed |
| US-20100068178-A1 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | LAILA NUTRACEUTICALS (IN) | 2010-03-18 | — | — | US | claimed |
| WO-2010029577-A2 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | GOKARAJU GANGA RAJU (IN) | 2010-03-18 | — | — | WO | claimed |
| EP-2324006-B1 | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD (IN) | 2014-08-13 | — | — | EP | disclosed |
| US-8258119-B2 | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | Kasina Laila Innova Pharmaceuticals (IN) | 2012-09-04 | — | — | US | disclosed |
| US-8258119-B2 | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | Kasina Laila Innova Pharmaceuticals (IN) | 2012-09-04 | — | — | US | disclosed |
| EP-2324006-A2 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | Kasina Laila Innova Pharmaceuticals Private Ltd. (IN) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010029577-A2 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | GOKARAJU GANGA RAJU (IN) | 2010-03-18 | — | — | WO | disclosed |
| US-20100068178-A1 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | LAILA NUTRACEUTICALS (IN) | 2010-03-18 | — | — | US | disclosed |
| US-20100068178-A1 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | LAILA NUTRACEUTICALS (IN) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068178-A1 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | BRAF, NRAS, TP53 | BCAT2 3189/4885ALDH1A1 731/4885LMNA 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.